ArticleCell reports2026
An accessory orthosteric ligand binding site in the (α3)
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The α3β4 nicotinic acetylcholine receptor (nAChR) is a heteropentameric ligand-gated channel whose distribution includes reward circuits of the brain, where it regulates expression of drug withdrawal symptoms. α3β4 nAChRs form two stoichiometries in the absence of other subunits, containing orthosteric binding sites between the primary α3 and the adjacent β4 subunit. The identity of the fifth (accessory) subunit is different between the two stoichiometries, but it is unknown whether this structural nuance yields any biophysical differences. To investigate this, we constrained receptor stoichiometry by engineering an α3β4 tandem dimer and co-expressing it in HEK293T cells with a select fifth subunit. We then used substituted-cysteine accessibility to covalently modify the primary and accessory binding sites. This approach revealed a functional "accessory orthosteric" site at the α3-α3 interface of (α3)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.